Marco
Grrrrrrr!
- Messages
- 2,386
- Location
- Near Cognac, France
This is very interesting in a number of respects. As I understand it :
A proportion of rheumatoid arthritis have a defective immune protection against EBV;
A proportion of RA patients have active EBV infection in B cells and bone marrow;
Treatment of RA patients with rituximab (RTX) leads to a greater improvement in symptoms in those with active EBV infection compared to EBV negative patients;
EBV may play a part in the etiology of RA either directly or through initiating an autoimmune response :
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936947/?tool=pubmed
A proportion of rheumatoid arthritis have a defective immune protection against EBV;
A proportion of RA patients have active EBV infection in B cells and bone marrow;
Treatment of RA patients with rituximab (RTX) leads to a greater improvement in symptoms in those with active EBV infection compared to EBV negative patients;
EBV may play a part in the etiology of RA either directly or through initiating an autoimmune response :
EpsteinBarr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment
Conclusions. EBV and parvovirus genomes are frequently found in bone marrow of RA patients. The presence of EBV genome was associated with a better clinical response to RTX. Thus, presence of EBV genome may predict clinical response to RTX.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936947/?tool=pubmed